AmpliPhi Biosciences
Armata Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant bacterial infections. The company aims to set the highest standards for safety and efficacy in phage-based treatments, addressing the global challenge of antibiotic resistance through innovative science and high-quality manufacturing. The company is actively involved in scientific research, regulatory discussions, and biofilm removal strategies related to bacteriophage therapy.
Industries
Nr. of Employees
small (1-50)
AmpliPhi Biosciences
5005 McConnell Ave, Los Angeles, CA 90066
Patents
Therapeutic bacteriophage compositions for treating Staphylococcus infection
US-12239677-B2
View DetailsTherapeutic bacteriophage compositions for treating Staphylococcus infection
US-11654166-B2
View Details
Therapeutic bacteriophage compositions for treating Staphylococcus infection
US-12239677-B2
View DetailsTherapeutic bacteriophage compositions for treating Staphylococcus infection
US-11654166-B2
View DetailsProducts
Investigational bacteriophage therapeutic programs (clinical-stage pipeline)
Clinical-stage investigational programs focused on pathogen-targeted bacteriophage therapies for antibiotic-resistant or difficult-to-treat bacterial infections.
Investigational bacteriophage therapeutic programs (clinical-stage pipeline)
Clinical-stage investigational programs focused on pathogen-targeted bacteriophage therapies for antibiotic-resistant or difficult-to-treat bacterial infections.
Services
Engagement and partnering discussions to explore licensing, collaboration, or development opportunities related to bacteriophage therapeutics.
Engagement and partnering discussions to explore licensing, collaboration, or development opportunities related to bacteriophage therapeutics.
Expertise Areas
- Bacteriophage therapeutics development
- Phage engineering and synthetic biology
- Formulation development and CMC for biologics
- cGMP clinical manufacturing and clinical trial material release
Key Technologies
- Bacteriophage isolation and characterization
- Synthetic biology for phage engineering
- Formulation development for biologics
- cGMP clinical-scale manufacturing
News & Updates
Deborah Birx appointed CEO
Deborah Birx, M.D., was appointed CEO of Armata on July 10, 2023, bringing extensive experience in global health and infectious diseases.
Armata's research on bacteriophage efficacy
Various studies and publications demonstrate the effectiveness of bacteriophages against multidrug-resistant bacteria.
Scientific and Regulatory Issues in Phage Therapy Workshop
A workshop discussing scientific and regulatory landscape for phage-based treatments.
Activity of Bacteriophages in Removing Biofilms of Pseudomonas aeruginosa
Research on bacteriophages and biofilms, highlighting their potential in biofilm removal from chronic rhinosinusitis patients.
Bacteriophages and Biofilms
Studies on the role of bacteriophages in biofilm disruption and bacterial eradication.
Addressing Antimicrobial Resistance with Phage Therapy
Armata's approach to combating antibiotic resistance through targeted bacteriophage therapeutics.
Deborah Birx appointed CEO
Deborah Birx, M.D., was appointed CEO of Armata on July 10, 2023, bringing extensive experience in global health and infectious diseases.
Armata's research on bacteriophage efficacy
Various studies and publications demonstrate the effectiveness of bacteriophages against multidrug-resistant bacteria.
Scientific and Regulatory Issues in Phage Therapy Workshop
A workshop discussing scientific and regulatory landscape for phage-based treatments.
Activity of Bacteriophages in Removing Biofilms of Pseudomonas aeruginosa
Research on bacteriophages and biofilms, highlighting their potential in biofilm removal from chronic rhinosinusitis patients.
Bacteriophages and Biofilms
Studies on the role of bacteriophages in biofilm disruption and bacterial eradication.
Addressing Antimicrobial Resistance with Phage Therapy
Armata's approach to combating antibiotic resistance through targeted bacteriophage therapeutics.